Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman Sells 2,000 Shares of Stock

Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman sold 2,000 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the completion of the sale, the director now owns 32,336 shares in the company, valued at approximately $4,656,707.36. The trade was a 5.82 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Glaukos Price Performance

Shares of GKOS stock opened at $138.82 on Friday. The stock has a 50-day moving average price of $136.25 and a 200 day moving average price of $126.81. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The firm has a market cap of $7.65 billion, a price-to-earnings ratio of -45.97 and a beta of 1.03. Glaukos Co. has a 12 month low of $65.00 and a 12 month high of $147.65.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. The firm had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The company’s revenue was up 23.9% on a year-over-year basis. During the same period last year, the company earned ($0.50) earnings per share. Research analysts expect that Glaukos Co. will post -1.89 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on GKOS. Truist Financial raised their price objective on shares of Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Piper Sandler set a $140.00 price target on shares of Glaukos in a research note on Thursday, October 17th. Stephens raised Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. Morgan Stanley cut Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a report on Monday, December 2nd. Finally, Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $132.00 to $162.00 in a report on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $143.17.

Hedge Funds Weigh In On Glaukos

Several institutional investors have recently modified their holdings of the stock. Cetera Advisors LLC acquired a new position in shares of Glaukos in the 1st quarter valued at approximately $213,000. Sequoia Financial Advisors LLC acquired a new position in shares of Glaukos in the 2nd quarter valued at approximately $229,000. Assenagon Asset Management S.A. acquired a new position in shares of Glaukos in the 2nd quarter valued at approximately $6,832,000. Raymond James & Associates grew its position in shares of Glaukos by 23.2% in the 2nd quarter. Raymond James & Associates now owns 13,017 shares of the medical instruments supplier’s stock valued at $1,541,000 after purchasing an additional 2,452 shares during the period. Finally, Fifth Third Wealth Advisors LLC acquired a new position in shares of Glaukos in the 2nd quarter valued at approximately $187,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.